Financial Counselors Inc. reduced its holdings in Celgene Corporation (NASDAQ:CELG) by 1.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 71,716 shares of the biopharmaceutical company’s stock after selling 1,019 shares during the quarter. Financial Counselors Inc.’s holdings in Celgene Corporation were worth $9,314,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Tdam USA Inc. grew its holdings in shares of Celgene Corporation by 2.1% during the first quarter. Tdam USA Inc. now owns 27,084 shares of the biopharmaceutical company’s stock worth $3,370,000 after buying an additional 570 shares in the last quarter. YorkBridge Wealth Partners LLC grew its holdings in shares of Celgene Corporation by 27.6% during the first quarter. YorkBridge Wealth Partners LLC now owns 11,915 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 2,574 shares in the last quarter. Wedbush Securities Inc. grew its holdings in shares of Celgene Corporation by 9.9% during the first quarter. Wedbush Securities Inc. now owns 30,877 shares of the biopharmaceutical company’s stock worth $3,842,000 after buying an additional 2,778 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Celgene Corporation during the first quarter worth about $4,250,000. Finally, First Personal Financial Services grew its holdings in shares of Celgene Corporation by 2.5% during the first quarter. First Personal Financial Services now owns 2,913 shares of the biopharmaceutical company’s stock worth $362,000 after buying an additional 70 shares in the last quarter. Institutional investors own 79.16% of the company’s stock.

Celgene Corporation (NASDAQ CELG) opened at $98.86 on Wednesday. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The company has a market capitalization of $79,644.98, a price-to-earnings ratio of 15.81, a price-to-earnings-growth ratio of 0.78 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the company earned $1.58 EPS. The company’s revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.

A number of research analysts recently issued reports on CELG shares. Vetr downgraded Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a report on Tuesday, August 29th. Royal Bank Of Canada decreased their price objective on Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating for the company in a report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a report on Friday, October 20th. Morgan Stanley reduced their price target on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating for the company in a research report on Monday, October 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $139.64.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,227 shares of company stock worth $2,843,956. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Holdings Lessened by Financial Counselors Inc.” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/15/celgene-corporation-celg-holdings-lessened-by-financial-counselors-inc.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.